DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quinaretic (Quinapril Hydrochloride / Hydrochlorothiazide) - Summary

 
 



BOXED WARNING

USE IN PREGNANCY

When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, QUINARETIC should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality.

 

QUINARETIC SUMMARY

QUINARETIC is a fixed-combination tablet that combines an angiotensin-converting enzyme (ACE) inhibitor, quinapril hydrochloride, and a thiazide diuretic, hydrochlorothiazide.

QUINARETIC is indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).

In using QUINARETIC, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis).

Angioedema in Black Patients:

Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.


See all Quinaretic indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Quinaretic (Quinapril / Hydrochlorothiazide)

Prehypertension in late pregnancy linked to poorer fetal outcomes
Source: Hypertension News From Medical News Today [2016.02.02]
Women who develop prehypertension after 36 weeks' gestation may be at greater risk of having a stillbirth or an underweight infant, according to researchers from Sweden.

Easily stressed teens have increased hypertension risk later in life
Source: Hypertension News From Medical News Today [2016.02.02]
Being an easily stressed 18-year-old might predict high blood pressure later in life, according to a study following the health of 1.5 million Swedish men.

Actelion receives Health Canada approval for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.01.26]
Actelion has announced that Health Canada has granted a Notice of Compliance (NOC) approving the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag),originally discovered...

The age-related change of angiotensin receptor promotes hypertension
Source: Hypertension News From Medical News Today [2016.01.20]
Heterodimerization of AT1R with P2Y6R along with age promotes angiotensin II-induced hypertension.

Formulation scientists to rescue patients with pulmonary arterial hypertension
Source: Huntingtons Disease News From Medical News Today [2016.01.15]
Overview of a type of high blood pressure of the arteries of the lungs and the heart and a new patient-friendly inhalation treatment.

more news >>


Page last updated: 2016-02-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015